Industry Overview - Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States, with independent pharmacists reporting a two-thirds decline in RSV vaccine uptake compared to the previous year [1][3] - RSV poses a severe health risk to infants, older adults, and individuals with compromised immune systems, leading to numerous hospitalizations and deaths annually [2] Company Performance - GSK's sales for Arexvy, the first RSV vaccine approved in May of last year, might fall short of Wall Street's expectations for Q3, with a spokesperson remaining optimistic about the vaccine's growth potential [4] - In 2023, GSK achieved $1.564 billion in RSV vaccine sales, while Pfizer recorded $890 million, half of GSK's figures [5] - Market predictions suggest a slight decrease in GSK's sales to approximately $1.5 billion this year, whereas Pfizer's sales are expected to rise nearly 40% to $1.2 billion [5] Regulatory Impact - The decline in RSV vaccine demand is attributed to a CDC decision in June that narrowed its recommendations for older adults, refraining from advising those under 60 to receive the vaccine [3]

GSK plc (GSK) announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older). The study achieved its primary endpoint of non-inferior immune response — study participants who received the co-administered shot generated immune responses that were similar to those generated in participants who received each vaccine separately. Study participants who received t ...

Core Insights - Kalm Therapeutics has appointed Dr. Tomoko Maeda-Chubachi as Chief Medical Officer to oversee the design and submission of their Phase 1b/2a clinical trial protocol to the FDA [1][4] Company Overview - Kalm Therapeutics, founded in 2024, is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of mild to moderate atopic dermatitis and psoriasis [4] Leadership Experience - Dr. Maeda-Chubachi has extensive experience in dermatology drug development, having worked with Pfizer, Eli Lilly, and GSK, where she led the Phase II clinical trial of the eczema/psoriasis topical cream Vtama, which was acquired by Dermavant for $250 million [3] - Most recently, she served as Chief Medical Officer at Pelthos Therapeutics, where she led the approval of Zelsuvmi for molluscum contagiosum [3] Industry Context - Eczema remains a complex disease requiring diverse therapeutic options, and Dr. Maeda-Chubachi expressed excitement about developing the Kalm Patch as a new management solution for eczema [2]

GSK plc (GSK) announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary endpoint in the combined phase I/II proof-of-concept study. The phase I/II TH HSV REC-003 study evaluated the clinical efficacy of the early-stage HSV vaccine candidate GSK3943104. The company completed the primary objective data analysis from the phase II part of the phase I/II TH HSV REC-003 study, which demonstrated that GSK3943104 failed to meet the study's primary efficacy end ...

GSK's (GSK) phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint. Data from the MATINEE study showed that in patients treated for up to 2 years, the addition of Nucala to inhaled maintenance therapy led to a statistically significant and clinically meaningful reduction in the annualized rate of moderate/severe exacerbations versus placebo, thereby meeting the study's primary endpoint. C ...

GSK plc (GSK) has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 50-59 years who are at increased risk of the disease. In the European Union (EU), there are around 65 million adults aged 50-59 years who are at increased risk for RSV disease. Out of these, an estimated 20 mil ...

GSK (GSK) stock has risen 18.5% so far this year compared with an increase of 27.1% for the industry. The stock has also been consistently trading above its 50-day and 200-day moving averages since mid-August. Zacks Investment Research Image Source: GSK Stock Movement in 2024 So Far GSK boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development. In July 2022, GSK de-merged its Consumer Healthcare segment into ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores ...

Core Insights - GSK's stock price has shown volatility, with a notable rise of over 16% following Q1 2024 results, but faced a decline of almost 9% due to Zantac-related litigation concerns [1][2] - The company's H1 2024 results exceeded expectations, indicating strong fundamentals despite ongoing legal risks [1][2] Financial Performance - Healthy sales growth was reported, with turnover excluding COVID-19 solutions increasing by 13% year-on-year (YoY) in both H1 2024 and Q2 2024 at constant exchange rates (CER), consistent with the 14% growth in 2023 [2][4] - Core earnings per share (EPS) grew by 20% YoY at CER, although growth softened to 13% YoY in Q2 2024, still surpassing initial projections of 6-9% [4][5] - GSK has upgraded its full-year outlook, now expecting turnover growth of 8% and core EPS growth of 11% [5][6] Future Outlook - Despite positive H1 2024 results, a slowdown is anticipated in H2 2024, with turnover expected to contract by 5% YoY and core EPS declining by 9% YoY [6][7] - The company attributes this expected slowdown to the annualization of product launches and stocking impacts, particularly in Vaccines and Oncology [7][8] - GSK's Specialty Medicines segment remains strong, contributing 37% of revenues in H1 2024 with a 20% YoY increase [10][11] Stock Metrics - The forward non-GAAP price-to-earnings (P/E) ratio is projected at 8.9x, indicating significant potential upside compared to the five-year average P/E of approximately 13x [12] - GSK has increased its dividend payout by 3.4% for 2024, resulting in a forward dividend yield of 3.9%, which is favorable compared to the healthcare sector median yield of 1.4% [13][14] Investment Considerations - GSK's strong H1 2024 performance and upgraded outlook make it an attractive investment, although risks related to expected weak performance in H2 2024 and ongoing Zantac litigation may temper enthusiasm [15][16]

Financial Data and Key Metrics - Sales grew 13% to £7.9 billion in Q2 2024, with core operating profit up 21% to £2.5 billion and core earnings per share rising 17% to 43.4p, all excluding COVID solutions [3] - The company upgraded its full-year guidance, expecting sales growth of 7% to 9% and core operating profit growth of 11% to 13% for 2024 [6][29] - For 2026, the company expects more than 7% sales growth and more than 11% core operating profit growth, with sales projected to exceed £38 billion by 2031 [7] Business Line Performance - Vaccines sales grew 3% in Q2, excluding COVID solutions, with Shingrix delivering £832 million despite a 4% decline in the quarter [16] - Specialty Medicines sales increased by 22%, driven by strong performance in oncology and HIV treatments, with Nucala up 17% and Benlysta up 20% [18] - General Medicines grew by 12% in Q2, with Trelegy sales increasing 41% to £842 million, driven by channel and segment mix adjustments [20] Market Performance - In the U.S., sales grew 17%, with Shingrix sales declining 36% due to channel inventory reductions and changes in retail vaccine prioritization [16] - Outside the U.S., Shingrix sales grew significantly, representing 64% of Q2 revenue, with strong performance in Australia, Europe, and China [16] - Arexvy, the RSV vaccine, has vaccinated nearly 8 million people since launch, maintaining around 2/3 of the retail vaccination share [17] Company Strategy and Industry Competition - The company continues to invest in its pipeline, with 70 assets in clinical development, focusing on vaccines, oncology, and respiratory treatments [8][9] - GSK is advancing its long-acting HIV medicines, with plans to deliver the first ultra-long-acting 4-monthly treatment regimen by 2027 [23] - The company is also progressing in oncology, with Blenrep showing potential to become the new standard of care for multiple myeloma [13] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the medium-term outlook for the vaccines portfolio, despite short-term impacts, and expects growth to come from outside the U.S. [33][40] - The company is focused on delivering differentiated health impact and attractive returns for shareholders, with a strong pipeline and strategic investments in key therapeutic areas [32] - Management highlighted the importance of cost discipline and operational efficiency, which have driven margin improvements and strong cash flow generation [26][27] Other Important Information - The company launched faenoquine in Thailand and Brazil, the first single-dose radical dual medicine to prevent malaria relapse [5] - GSK is conducting a Phase III trial for a low-carbon version of its metered-dose inhaler Ventolin, which could reduce emissions by around 90% [5] - The company is also progressing in ESG initiatives, including partnerships to fight antimicrobial resistance and reduce carbon emissions [5] Q&A Session Summary Question: Vaccine dynamics in China and U.S. Shingrix growth [33] - In China, Shingrix has expanded to 19,000 points of vaccination and is on track for 27,000 by year-end, with strong demand expected in key cities [34][35] - In the U.S., Shingrix sales declined due to channel inventory reductions and CMS rule changes, but growth is expected in the second half of 2024 [36][37] Question: Arexvy contracting and revaccination [45][54] - The company is confident in Arexvy's long-term potential, with peak sales expected to exceed £3 billion, driven by global rollout and strong data [17][49] - Revaccination data for Arexvy will be presented later this year, with the company awaiting full data to determine the need for boosters [57] Question: Zantac litigation and potential settlement [70] - The company reiterated its commitment to defending against Zantac claims, with no change to its growth agenda or investment plans [70] Question: Competition in China and Arexvy's potential [72] - Local competition in China is limited, with Shingrix maintaining a strong position due to its efficacy and target market [74] - The company is exploring opportunities to expand its collaboration with Japan rand to include Arexvy [74] Question: HIV guidance and long-acting therapies [78] - The company expects double-digit growth in HIV for the third consecutive year, with long-acting therapies expected to drive future growth [79] Question: Mechanism for lower dementia incidence with Shingrix [82] - The potential mechanism for reduced dementia risk with Shingrix is still under investigation, with vascular and viral reactivation hypotheses being explored [82]